Most importantly, the tumor subtypes with HRAS mutations show high expression levels of PD-L1, which indicates that alterations in tumor cells and TME by tipifarnib can be reversed by PD-1/PD-L1 immune checkpoint inhibitors. The gene discussed is CD274; the disease is neoplasm.